Peroxisome proliferator-activated receptor - Gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: Association with clinicopathological parameters, tumor proliferative capacity, and patients' survival

Medical Science Monitor

Volumn 15, Issue 5, 2009, Pages

  Giaginis, Constantinos ^a,b   Katsamangou, Eleftheria ^a,c   Tsourouflis, Gerasimos ^b   Zizi Serbetzoglou, Diamanto ^c   Kouraklis, Gregorios ^b   Theocharis, Stamatios ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Tzaneio General Hospital   (Greece)

Author keywords

Clinicopathological parameters; Immunohistochemistry; Pancreatic adenocarcinoma; Patients' survival; PPAR gamma; RXR alpha

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; STAINING; TUMOR VOLUME;

ADENOCARCINOMA; AGED; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PPAR GAMMA; RETINOID X RECEPTORS; SURVIVAL ANALYSIS;

EID: 66649131659     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Nolte RT, Wisely GB, Westin S et al: Ligand binding and co-activator assembly of the peroxisome proliferators activated receptor-γ. Nature, 1998; 395: 137-143 (Pubitemid 28425645)
2. Willson TM, Brown PJ, Strenbach DD, Henke BR: The PPARs: From orphan receptors to drug discovery. J Med Chem, 2000; 43: 527-550 (Pubitemid 30127149)
3. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev, 1999; 20: 649-688 (Pubitemid 30650602)
4. Feige JN, Gelman L, Michalik L et al: From: molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res, 2006; 45: 120-159 (Pubitemid 43248732)
5. Feinstein DL, Spangolo A, Akar C et al: Receptor-independent actions of PPAR thiazolidinedione agonists: Is a mitochondrial function the key? Biochem Pharmacol, 2005; 70: 177-188
6. Germain P, Chambon P, Eichele G et al: International Union of Pharmacology. LXIII Retinoid X Receptors. Pharmacol Rev, 2006; 58: 760-772
7. Szanto A, Narkar V, Shen Q et al: Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ, 2004; 2: S126-43 (Pubitemid 40163969)
8. Braissant O, Foufelle F, Scotto C et al: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β and -γ in the adult rat. Endocrinology, 1996; 137: 354-366
9. Kliewer SA, Forman BM, Blumberg B et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA, 1994; 91: 7355-7359 (Pubitemid 24226862)
10. Wysowski DK, Armstrong G, Governale L: Rapid increase in the use of oral Antidiabetic drugs in the United States, 1990-2001. Diabetes Care, 2003; 26: 1852-1855
11. Theocharis S, Margeli A, Vielh P, Kouraklis G: Peroxisome proliferator- activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev, 2004; 30: 545-554 (Pubitemid 39157854)
12. Giaginis C, Margeli A, Theocharis S: Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) ligands as investigational modulators of angiogenesis. Expert Opin Investig Drug, 2007; 16: 1561-1572
13. Giaginis C, Tsantili-Kakoulidou A, Theocharis S: Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer. PPAR Res, 2008; 2008: 431763
14. Jemal A, Siegel E, Ward E et al: Cancer statistics, 2006. CA Cancer J Clin, 2006; 56: 106-130
15. Sener DB, Jessup JM, Colacchio T: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using National Cancer Database. J Am Coll Surg, 1999; 189: 1-7
16. Sarkar FH, Banerjee S, Li Y: Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol, 2007; 224: 326-336 (Pubitemid 47575667)
17. Kawa S, Nikaido T, Unno H et al: Growth inhibition and differentiation of pancreatic cell lines by PPAR-gamma ligand troglitazone. Pancreas, 2002; 24: 1-7 (Pubitemid 34019653)
18. Sawai H, Liu J, Reber HA et al: Activation of peroxisome proliferator-activated receptor-γ decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res, 2006; 4: 159-167
19. Kristiansen G, Jacob J, Buckendahl AC et al: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res, 2006; 12: 6444-6451 (Pubitemid 44799717)
20. Balasubramanian S, Chandraratna RAS, Eckert R: Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. Carcinogenesis, 2004; 25: 1377-1385 (Pubitemid 39162704)
21. Rosewicz S, Stier U, Brembeck F et al: Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology, 1995; 109: 1646-1660
22. nd ed. Berlin, Springer, 1996
23. Giaginis C, Davides D, Zarros A et al: Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma. Dig Dis Sci, 2008; 53(6): 1728-1734
24. Theocharis S, Giaginis C, Parasi A et al: Expression of Peroxisome Proliferator-Activated Receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle related molecules and patients' survival. Dig Dis Sci, 2007; 52: 2305-2311 (Pubitemid 47246534)
25. Theocharis S, Kanelli H, Politi E et al: Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer, 2002; 36: 49-55 (Pubitemid 34497122)
26. Eible G, Reber HA, Hines OJ, Go VLW: COX and PPAR: Possible interactions in pancreatic cancer. Pancreas, 2004; 29: 247-253 (Pubitemid 40228269)
27. Itami A, Watanabe G, Shimada Y et al: Ligands for Peroxisome proliferator- activated receptor g inhibits growth of pancreatic cancers both in vitro and in vivo. Int J Cancer, 2001; 94: 370-376 (Pubitemid 32906067)
28. Jiang WG, Redfern A, Bryce RP, Mansel RE: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids, 2000; 62: 119-127 (Pubitemid 30216391)
29. Katagiri Y, Takeda K, Yu ZX et al: Modulation of retinoid signaling through NGF-induced nuclear export of NGFI-B. Nat Cell Biol, 2000; 2: 435-440
30. Sarraf P, Mueller E, Smith WM et al: Loss-of-function mutations in PPARa associated with human colon cancer. Molecular Cell, 1999; 3: 799-804 (Pubitemid 29323058)
31. Chang TH, Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non small cell lung cancer. Cancer Res, 2000; 60: 1129-1138 (Pubitemid 30129556)
32. Takiyama Y, Miyokawa N, Sugawara A et al: Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. J Clin Endocrinol Metab, 2004; 89: 5851-5861 (Pubitemid 39518481)
33. Geni E, Mello T, Tarocchi M et al: Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. World J Gastroenterol, 2005; 11: 1122-1130 (Pubitemid 40352997)
34. Hashimoto K, Ethridge RT, Evers BM: Peroxisome proliferator-activated receptor γ ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int J Gastrointest Cancer, 2002; 32: 7-22 (Pubitemid 36323098)
35. Hashimoto K, Farrow BJ, Evers BM: Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2. Pancreas, 2004; 28: 153-159 (Pubitemid 38269775)
36. Motamura W, Okumura T, Takahashi N et al: Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increases of p27Kip1 in human pancreatic carcinoma cells. Cancer Res, 2000; 60: 5558-5564
37. Motamura W, Nagamine M, Tanno S et al: Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. J Gastroenterol, 2004; 39: 461-468 (Pubitemid 38811730)
38. Obara W, Konda R, Akasaka S et al: Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma. J Urol, 2007; 178: 1497-1503 (Pubitemid 47368384)
39. Singh RR, Gururaj AE, Vadlamudi RK, Kumar R: 9-cis-retinoic acid upregulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway. J Biol Chem, 2006; 281: 15394-15404 (Pubitemid 43855131)
40. Albrechtsson E, Ohlsson B, Axelson J: The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. Pancreas, 2002; 25: 49-56
41. Yen W-C, Prudente RY, Lamph WW: Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat, 2004; 88: 141-148 (Pubitemid 39575571)
42. Rendi MH, Suh N, Lamph WW et al: The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res 2004; 64: 3566-3571 (Pubitemid 38657933)
43. Fu J, Ding Y, Huang D et al: The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer. Cancer Lett, 2007; 248: 153-163 (Pubitemid 46319348)
44. Tsujie M, Nakamori S, Okami J et al: Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor γ/retinoid X receptor α pathway. Exp Cell Res, 2003; 289: 143-151 (Pubitemid 36993844)
45. Toyota M, Miyazaki Y, Kitamura S et al: Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci, 2002; 70: 1565-1575 (Pubitemid 34164550)
46. Yamazaki K, Shimizu M, Okuno M et al: Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut, 2007; 56: 1557-1563 (Pubitemid 350033194)
47. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK:In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer, 2006; 5: 13